ProCE Banner Activity


Meningococcal Disease: A Deadly, Unpredictable but Preventable Disease

Clinical Thought
When you see a patient with a fever, headache, vomiting, you wonder, “Is this a virus or could it be a meningococcal infection?” Invasive meningococcal disease is unpredictable and can turn deadly quick. Read my commentary about the importance of meningococcal vaccinations.

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: September 22, 2022

Expiration: September 21, 2023

No longer available for credit.



Gary S. Marshall

Gary S. Marshall, MD

Professor of Pediatrics
Division of Pediatric Infectious Diseases
University of Louisville School of Medicine
Louisville, Kentucky

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by an educational grant from

Sanofi Pasteur


Society of Adolescent Health and Medicine

ProCE Banner

Target Audience

This program is intended for physicians and other healthcare professionals who care for adolescents eligible for meningococcal vaccination.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Formulate plans to address barriers to improve adolescent meningococcal immunization rates despite limited patient encounters, such as utilizing the 16-year-old immunization platform and encouraging catch-up vaccination whenever possible


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Gary S. Marshall, MD

Professor of Pediatrics
Division of Pediatric Infectious Diseases
University of Louisville School of Medicine
Louisville, Kentucky

Gary S. Marshall, MD: consultant/advisor/speaker: GlaxoSmithKline, Merck, Pfizer, Sanofi, Seqirus; researcher: GlaxoSmithKline, Merck, Pfizer, Sanofi.

Staff Disclosure


Jeanne Forrester, PharmD, BCPS, BCIDP

Jeanne Forrester, PharmD, BCPS, BCIDP, has no relevant financial relationships to disclose.

Swathi K,

Editorial Contributor

Swathi K has no relevant financial relationships to disclose.

Jacqueline Meredith, PharmD, BCIDP

Scientific Director

Jacqueline Meredith, PharmD, BCIDP, has no relevant financial relationships to disclose.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS has no relevant financial relationships to disclose.

Instructions for Credit


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 22, 2022, through September 21, 2023:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


The goal of this program is to equip healthcare professionals with knowledge regarding meningococcal disease and vaccines and to provide practical tools to overcome barriers to immunization in adolescents, including reinforcing the importance of series completion and optimization of the 16-year-old immunization platform.